aluates Reports

$ 0.0

Automative

Global Oncology Drugs Market Research Report 2024

Published Date: January 2024

Report Code: QYRE-Auto-4R430

Global Oncology Drugs Market Size Status and Forecast 2021 2027

BUY CHAPTERS

Global Oncology Drugs Market Research Report 2024

Code: QYRE-Auto-4R430

Report

January 2024

Pages:107

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Astrazeneca plc

Sanofi

Novartis

Celgene

Bristol–Myers Squibb

Johnson & Johnson

Merck

Pfizer Inc

Amgen Inc

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen S A

Bayer

Biogen Idec

TEVA

Otsuka

Eisai Co Ltd

Merck KGaA

Gilead Sciences

Oncology Drugs Market Size

The global Oncology Drugs market was valued at US$ 197440 million in 2023 and is anticipated to reach US$ 395270 million by 2030, witnessing a CAGR of 10.3% during the forecast period 2024-2030.

Oncology Drugs Market

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.

The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.

Report Scope

The Oncology Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Oncology Drugs Market Report

Report Metric	Details
Report Name	Oncology Drugs Market
Accounted market size in 2023	US$ 197440 million
Forecasted market size in 2030	US$ 395270 million
CAGR	10.3%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Chemotherapy Targeted Therapy Immunotherapy (Biologic Therapy) Hormonal Therapy Others
Segment by Application	Blood Cancer Breast Cancer Gastrointestinal Cancer Prostate Cancer Respiratory or Lung Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Oncology Drugs Market growing?

Ans: The Oncology Drugs Market witnessing a CAGR of 10.3% during the forecast period 2024-2030.

What is the Oncology Drugs Market size in 2030?

Ans: The Oncology Drugs Market size in 2030 will be US$ 395270 million.

What is the Roche, Celgene, Novartis share in Oncology Drugs Market?

Ans: The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues.

What is the Oncology Drugs Market share by region?

Ans: By region, North America had the highest share of income, at 43%.

Who are the main players in the Oncology Drugs Market report?

Ans: The main players in the Oncology Drugs Market are Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences

What are the Application segmentation covered in the Oncology Drugs Market report?

Ans: The Applications covered in the Oncology Drugs Market report are Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory or Lung Cancer, Others

What are the Type segmentation covered in the Oncology Drugs Market report?

Ans: The Types covered in the Oncology Drugs Market report are Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oncology Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Chemotherapy

1.2.3 Targeted Therapy

1.2.4 Immunotherapy (Biologic Therapy)

1.2.5 Hormonal Therapy

1.2.6 Others

1.3 Market by Application

1.3.1 Global Oncology Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Blood Cancer

1.3.3 Breast Cancer

1.3.4 Gastrointestinal Cancer

1.3.5 Prostate Cancer

1.3.6 Respiratory or Lung Cancer

1.3.7 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Oncology Drugs Market Perspective (2019-2030)

2.2 Oncology Drugs Growth Trends by Region

2.2.1 Global Oncology Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Oncology Drugs Historic Market Size by Region (2019-2024)

2.2.3 Oncology Drugs Forecasted Market Size by Region (2025-2030)

2.3 Oncology Drugs Market Dynamics

2.3.1 Oncology Drugs Industry Trends

2.3.2 Oncology Drugs Market Drivers

2.3.3 Oncology Drugs Market Challenges

2.3.4 Oncology Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oncology Drugs Players by Revenue

3.1.1 Global Top Oncology Drugs Players by Revenue (2019-2024)

3.1.2 Global Oncology Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Oncology Drugs Revenue

3.4 Global Oncology Drugs Market Concentration Ratio

3.4.1 Global Oncology Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oncology Drugs Revenue in 2023

3.5 Oncology Drugs Key Players Head office and Area Served

3.6 Key Players Oncology Drugs Product Solution and Service

3.7 Date of Enter into Oncology Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Oncology Drugs Breakdown Data by Type

4.1 Global Oncology Drugs Historic Market Size by Type (2019-2024)

4.2 Global Oncology Drugs Forecasted Market Size by Type (2025-2030)

5 Oncology Drugs Breakdown Data by Application

5.1 Global Oncology Drugs Historic Market Size by Application (2019-2024)

5.2 Global Oncology Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Oncology Drugs Market Size (2019-2030)

6.2 North America Oncology Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Oncology Drugs Market Size by Country (2019-2024)

6.4 North America Oncology Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oncology Drugs Market Size (2019-2030)

7.2 Europe Oncology Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Oncology Drugs Market Size by Country (2019-2024)

7.4 Europe Oncology Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Oncology Drugs Market Size (2019-2030)

8.2 Asia-Pacific Oncology Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Oncology Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Oncology Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Oncology Drugs Market Size (2019-2030)

9.2 Latin America Oncology Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Oncology Drugs Market Size by Country (2019-2024)

9.4 Latin America Oncology Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oncology Drugs Market Size (2019-2030)

10.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Oncology Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Oncology Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Detail

11.1.2 Roche Business Overview

11.1.3 Roche Oncology Drugs Introduction

11.1.4 Roche Revenue in Oncology Drugs Business (2019-2024)

11.1.5 Roche Recent Development

11.2 Celgene

11.2.1 Celgene Company Detail

11.2.2 Celgene Business Overview

11.2.3 Celgene Oncology Drugs Introduction

11.2.4 Celgene Revenue in Oncology Drugs Business (2019-2024)

11.2.5 Celgene Recent Development

11.3 Novartis

11.3.1 Novartis Company Detail

11.3.2 Novartis Business Overview

11.3.3 Novartis Oncology Drugs Introduction

11.3.4 Novartis Revenue in Oncology Drugs Business (2019-2024)

11.3.5 Novartis Recent Development

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Detail

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb Oncology Drugs Introduction

11.4.4 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2019-2024)

11.4.5 Bristol-Myers Squibb Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Detail

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Oncology Drugs Introduction

11.5.4 Johnson & Johnson Revenue in Oncology Drugs Business (2019-2024)

11.5.5 Johnson & Johnson Recent Development

11.6 Merck & Co.

11.6.1 Merck & Co. Company Detail

11.6.2 Merck & Co. Business Overview

11.6.3 Merck & Co. Oncology Drugs Introduction

11.6.4 Merck & Co. Revenue in Oncology Drugs Business (2019-2024)

11.6.5 Merck & Co. Recent Development

11.7 AstraZeneca

11.7.1 AstraZeneca Company Detail

11.7.2 AstraZeneca Business Overview

11.7.3 AstraZeneca Oncology Drugs Introduction

11.7.4 AstraZeneca Revenue in Oncology Drugs Business (2019-2024)

11.7.5 AstraZeneca Recent Development

11.8 Pfizer

11.8.1 Pfizer Company Detail

11.8.2 Pfizer Business Overview

11.8.3 Pfizer Oncology Drugs Introduction

11.8.4 Pfizer Revenue in Oncology Drugs Business (2019-2024)

11.8.5 Pfizer Recent Development

11.9 Amgen

11.9.1 Amgen Company Detail

11.9.2 Amgen Business Overview

11.9.3 Amgen Oncology Drugs Introduction

11.9.4 Amgen Revenue in Oncology Drugs Business (2019-2024)

11.9.5 Amgen Recent Development

11.10 Eli Lilly

11.10.1 Eli Lilly Company Detail

11.10.2 Eli Lilly Business Overview

11.10.3 Eli Lilly Oncology Drugs Introduction

11.10.4 Eli Lilly Revenue in Oncology Drugs Business (2019-2024)

11.10.5 Eli Lilly Recent Development

11.11 AbbVie

11.11.1 AbbVie Company Detail

11.11.2 AbbVie Business Overview

11.11.3 AbbVie Oncology Drugs Introduction

11.11.4 AbbVie Revenue in Oncology Drugs Business (2019-2024)

11.11.5 AbbVie Recent Development

11.12 Takeda

11.12.1 Takeda Company Detail

11.12.2 Takeda Business Overview

11.12.3 Takeda Oncology Drugs Introduction

11.12.4 Takeda Revenue in Oncology Drugs Business (2019-2024)

11.12.5 Takeda Recent Development

11.13 Astellas

11.13.1 Astellas Company Detail

11.13.2 Astellas Business Overview

11.13.3 Astellas Oncology Drugs Introduction

11.13.4 Astellas Revenue in Oncology Drugs Business (2019-2024)

11.13.5 Astellas Recent Development

11.14 Ipsen

11.14.1 Ipsen Company Detail

11.14.2 Ipsen Business Overview

11.14.3 Ipsen Oncology Drugs Introduction

11.14.4 Ipsen Revenue in Oncology Drugs Business (2019-2024)

11.14.5 Ipsen Recent Development

11.15 Sanofi

11.15.1 Sanofi Company Detail

11.15.2 Sanofi Business Overview

11.15.3 Sanofi Oncology Drugs Introduction

11.15.4 Sanofi Revenue in Oncology Drugs Business (2019-2024)

11.15.5 Sanofi Recent Development

11.16 Bayer

11.16.1 Bayer Company Detail

11.16.2 Bayer Business Overview

11.16.3 Bayer Oncology Drugs Introduction

11.16.4 Bayer Revenue in Oncology Drugs Business (2019-2024)

11.16.5 Bayer Recent Development

11.17 Biogen Idec

11.17.1 Biogen Idec Company Detail

11.17.2 Biogen Idec Business Overview

11.17.3 Biogen Idec Oncology Drugs Introduction

11.17.4 Biogen Idec Revenue in Oncology Drugs Business (2019-2024)

11.17.5 Biogen Idec Recent Development

11.18 Teva

11.18.1 Teva Company Detail

11.18.2 Teva Business Overview

11.18.3 Teva Oncology Drugs Introduction

11.18.4 Teva Revenue in Oncology Drugs Business (2019-2024)

11.18.5 Teva Recent Development

11.19 Otsuka

11.19.1 Otsuka Company Detail

11.19.2 Otsuka Business Overview

11.19.3 Otsuka Oncology Drugs Introduction

11.19.4 Otsuka Revenue in Oncology Drugs Business (2019-2024)

11.19.5 Otsuka Recent Development

11.20 Eisai

11.20.1 Eisai Company Detail

11.20.2 Eisai Business Overview

11.20.3 Eisai Oncology Drugs Introduction

11.20.4 Eisai Revenue in Oncology Drugs Business (2019-2024)

11.20.5 Eisai Recent Development

11.21 Merck KGaA

11.21.1 Merck KGaA Company Detail

11.21.2 Merck KGaA Business Overview

11.21.3 Merck KGaA Oncology Drugs Introduction

11.21.4 Merck KGaA Revenue in Oncology Drugs Business (2019-2024)

11.21.5 Merck KGaA Recent Development

11.22 Gilead Sciences

11.22.1 Gilead Sciences Company Detail

11.22.2 Gilead Sciences Business Overview

11.22.3 Gilead Sciences Oncology Drugs Introduction

11.22.4 Gilead Sciences Revenue in Oncology Drugs Business (2019-2024)

11.22.5 Gilead Sciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Roche

Astrazeneca plc

Sanofi

Novartis

Celgene

Bristol–Myers Squibb

Johnson & Johnson

Merck

Pfizer Inc

Amgen Inc

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen S A

Bayer

Biogen Idec

TEVA

Otsuka

Eisai Co Ltd

Merck KGaA

Gilead Sciences

List of Tables

Table 1. Global Oncology Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Targeted Therapy

Table 4. Key Players of Immunotherapy (Biologic Therapy)

Table 5. Key Players of Hormonal Therapy

Table 6. Key Players of Others

Table 7. Global Oncology Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Oncology Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Oncology Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Oncology Drugs Market Share by Region (2019-2024)

Table 11. Global Oncology Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Oncology Drugs Market Share by Region (2025-2030)

Table 13. Oncology Drugs Market Trends

Table 14. Oncology Drugs Market Drivers

Table 15. Oncology Drugs Market Challenges

Table 16. Oncology Drugs Market Restraints

Table 17. Global Oncology Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Oncology Drugs Market Share by Players (2019-2024)

Table 19. Global Top Oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2023)

Table 20. Ranking of Global Top Oncology Drugs Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Oncology Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Oncology Drugs Product Solution and Service

Table 24. Date of Enter into Oncology Drugs Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Oncology Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Oncology Drugs Revenue Market Share by Type (2019-2024)

Table 28. Global Oncology Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Oncology Drugs Revenue Market Share by Type (2025-2030)

Table 30. Global Oncology Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Oncology Drugs Revenue Market Share by Application (2019-2024)

Table 32. Global Oncology Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Oncology Drugs Revenue Market Share by Application (2025-2030)

Table 34. North America Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Oncology Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Oncology Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Oncology Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Oncology Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Oncology Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Oncology Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Oncology Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Oncology Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Oncology Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Oncology Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Oncology Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Oncology Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 49. Roche Company Detail

Table 50. Roche Business Overview

Table 51. Roche Oncology Drugs Product

Table 52. Roche Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 53. Roche Recent Development

Table 54. Celgene Company Detail

Table 55. Celgene Business Overview

Table 56. Celgene Oncology Drugs Product

Table 57. Celgene Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 58. Celgene Recent Development

Table 59. Novartis Company Detail

Table 60. Novartis Business Overview

Table 61. Novartis Oncology Drugs Product

Table 62. Novartis Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 63. Novartis Recent Development

Table 64. Bristol-Myers Squibb Company Detail

Table 65. Bristol-Myers Squibb Business Overview

Table 66. Bristol-Myers Squibb Oncology Drugs Product

Table 67. Bristol-Myers Squibb Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 68. Bristol-Myers Squibb Recent Development

Table 69. Johnson & Johnson Company Detail

Table 70. Johnson & Johnson Business Overview

Table 71. Johnson & Johnson Oncology Drugs Product

Table 72. Johnson & Johnson Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 73. Johnson & Johnson Recent Development

Table 74. Merck & Co. Company Detail

Table 75. Merck & Co. Business Overview

Table 76. Merck & Co. Oncology Drugs Product

Table 77. Merck & Co. Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 78. Merck & Co. Recent Development

Table 79. AstraZeneca Company Detail

Table 80. AstraZeneca Business Overview

Table 81. AstraZeneca Oncology Drugs Product

Table 82. AstraZeneca Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 83. AstraZeneca Recent Development

Table 84. Pfizer Company Detail

Table 85. Pfizer Business Overview

Table 86. Pfizer Oncology Drugs Product

Table 87. Pfizer Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 88. Pfizer Recent Development

Table 89. Amgen Company Detail

Table 90. Amgen Business Overview

Table 91. Amgen Oncology Drugs Product

Table 92. Amgen Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 93. Amgen Recent Development

Table 94. Eli Lilly Company Detail

Table 95. Eli Lilly Business Overview

Table 96. Eli Lilly Oncology Drugs Product

Table 97. Eli Lilly Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 98. Eli Lilly Recent Development

Table 99. AbbVie Company Detail

Table 100. AbbVie Business Overview

Table 101. AbbVie Oncology Drugs Product

Table 102. AbbVie Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 103. AbbVie Recent Development

Table 104. Takeda Company Detail

Table 105. Takeda Business Overview

Table 106. Takeda Oncology Drugs Product

Table 107. Takeda Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 108. Takeda Recent Development

Table 109. Astellas Company Detail

Table 110. Astellas Business Overview

Table 111. Astellas Oncology Drugs Product

Table 112. Astellas Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 113. Astellas Recent Development

Table 114. Ipsen Company Detail

Table 115. Ipsen Business Overview

Table 116. Ipsen Oncology Drugs Product

Table 117. Ipsen Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 118. Ipsen Recent Development

Table 119. Sanofi Company Detail

Table 120. Sanofi Business Overview

Table 121. Sanofi Oncology Drugs Product

Table 122. Sanofi Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 123. Sanofi Recent Development

Table 124. Bayer Company Detail

Table 125. Bayer Business Overview

Table 126. Bayer Oncology Drugs Product

Table 127. Bayer Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 128. Bayer Recent Development

Table 129. Biogen Idec Company Detail

Table 130. Biogen Idec Business Overview

Table 131. Biogen Idec Oncology Drugs Product

Table 132. Biogen Idec Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 133. Biogen Idec Recent Development

Table 134. Teva Company Detail

Table 135. Teva Business Overview

Table 136. Teva Oncology Drugs Product

Table 137. Teva Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 138. Teva Recent Development

Table 139. Otsuka Company Detail

Table 140. Otsuka Business Overview

Table 141. Otsuka Oncology Drugs Product

Table 142. Otsuka Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 143. Otsuka Recent Development

Table 144. Eisai Company Detail

Table 145. Eisai Business Overview

Table 146. Eisai Oncology Drugs Product

Table 147. Eisai Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 148. Eisai Recent Development

Table 149. Merck KGaA Company Detail

Table 150. Merck KGaA Business Overview

Table 151. Merck KGaA Oncology Drugs Product

Table 152. Merck KGaA Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 153. Merck KGaA Recent Development

Table 154. Gilead Sciences Company Detail

Table 155. Gilead Sciences Business Overview

Table 156. Gilead Sciences Oncology Drugs Product

Table 157. Gilead Sciences Revenue in Oncology Drugs Business (2019-2024) & (US$ Million)

Table 158. Gilead Sciences Recent Development

Table 159. Research Programs/Design for This Report

Table 160. Key Data Information from Secondary Sources

Table 161. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Oncology Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Oncology Drugs Market Share by Type: 2023 VS 2030

Figure 3. Chemotherapy Features

Figure 4. Targeted Therapy Features

Figure 5. Immunotherapy (Biologic Therapy) Features

Figure 6. Hormonal Therapy Features

Figure 7. Others Features

Figure 8. Global Oncology Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Oncology Drugs Market Share by Application: 2023 VS 2030

Figure 10. Blood Cancer Case Studies

Figure 11. Breast Cancer Case Studies

Figure 12. Gastrointestinal Cancer Case Studies

Figure 13. Prostate Cancer Case Studies

Figure 14. Respiratory or Lung Cancer Case Studies

Figure 15. Others Case Studies

Figure 16. Oncology Drugs Report Years Considered

Figure 17. Global Oncology Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 18. Global Oncology Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 19. Global Oncology Drugs Market Share by Region: 2023 VS 2030

Figure 20. Global Oncology Drugs Market Share by Players in 2023

Figure 21. Global Top Oncology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2023)

Figure 22. The Top 10 and 5 Players Market Share by Oncology Drugs Revenue in 2023

Figure 23. North America Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. North America Oncology Drugs Market Share by Country (2019-2030)

Figure 25. United States Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Canada Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Europe Oncology Drugs Market Share by Country (2019-2030)

Figure 29. Germany Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. France Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. U.K. Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Italy Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Russia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Nordic Countries Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Asia-Pacific Oncology Drugs Market Share by Region (2019-2030)

Figure 37. China Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Japan Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. South Korea Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Southeast Asia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. India Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Australia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Latin America Oncology Drugs Market Share by Country (2019-2030)

Figure 45. Mexico Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Brazil Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East & Africa Oncology Drugs Market Share by Country (2019-2030)

Figure 49. Turkey Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Oncology Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Roche Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 52. Celgene Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 53. Novartis Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 55. Johnson & Johnson Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 56. Merck & Co. Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 57. AstraZeneca Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 58. Pfizer Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 59. Amgen Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 60. Eli Lilly Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 61. AbbVie Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 62. Takeda Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 63. Astellas Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 64. Ipsen Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 65. Sanofi Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 66. Bayer Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 67. Biogen Idec Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 68. Teva Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 69. Otsuka Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 70. Eisai Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 71. Merck KGaA Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 72. Gilead Sciences Revenue Growth Rate in Oncology Drugs Business (2019-2024)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions